You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 55 No. 11, November 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Special Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (19)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Statistics and Research Methods
 •Alzheimer Disease
 •Randomized Controlled Trial
 •Alert me on articles by topic

Is the Placebo Control Obsolete in a World After Donepezil and Vitamin E?

Jason H. T. Karlawish, MD; Peter J. Whitehouse, MD, PhD

Arch Neurol. 1998;55:1420-1424.

Recent clinical trials of donepezil and vitamin E have produced active therapeutic drugs for the treatment of patients with Alzheimer disease (AD). The AD research community is now in a gray zone between the absence of accepted therapies and the presence of completely effective therapies. How should these therapies guide the choice of the proper control for future AD clinical trials? The community equipoise principle can guide a process to answer this question. The principle is that a clinical trial should answer clinical questions that are valued by the community who will use the results of that trial. This means that the choice of the proper control for future AD clinical trials ought to be guided by the values of a community who will experience the results of those trials: physicians and patients or their representatives such as caregivers. The values of patients can be included by giving them a voice in the design and review of clinical trials. Community dialogue should be the norm for the design and review of AD clinical trials. We conclude with suggestions to foster this dialogue and issues that should be addressed.


From the Department of Medicine, Division of Geriatrics, Institute on Aging and Center for Bioethics, The University of Pennsylvania, Philadelphia (Dr Karlawish); and the Division of Behavioral and Geriatric Neurology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio (Dr Whitehouse).


RELATED ARTICLE

New Treatments in Alzheimer Disease and the Continued Need for Placebo-Controlled Trials
Martin R. Farlow
Arch Neurol. 1998;55(11):1396-1398.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Ethical aspects of placebo groups in pain trials: Lessons from psychiatry
Nagasako and Kalauokalani
Neurology 2005;65:S59-S65.
ABSTRACT | FULL TEXT  

Alternative Neurology
Rosenberg
Arch Neurol 1998;55:1394-1395.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.